Financial results: Bioxyne; Melodiol Global Health; Emyria; Zelira; Elixinol; Wellnex Life; Argent BioPharma by Steve Jones May 1, 2024May 1, 2024 Revenue generated by Breathe Life Sciences (BLS) slipped to A$1.7 million in Q3 FY24 with parent […]
Company news: Medibis; Althea; Elixinol; InhaleRx; Ecofibre; Aura Therapeutics; AusCann by Martin Lane April 4, 2024July 16, 2024
Ecofibre sells hemp food and animal products business to Elixinol by Martin Lane February 12, 2024July 16, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024February 7, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: Elixinol/The Sustainable Nutrition Group; Emyria by Steve Jones August 8, 2023April 30, 2024
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024